• en
  • it
  • de
  • UPDATE: Supply situation in view of the current COVID-19 outbreak

    PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running. PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system […]

    FarmaBios activities are regularly proceeding…

    During this critical and challenging period, Farmabios SpA states that our activities are regularly proceeding. We are conscious of the role and duty in delivering APIs, and our active part in the health system. We are doing our utmost to preserve our partners’ service continuously through our the work of our head quarter and manufacturing […]

    Breaking News: PharmaZell Group acquired by Bridgepoint

    The PharmaZell Group management is very pleased to inform that the Group was acquired by Bridgepoint from DPE Deutsche Private Equity and Maxburg Capital Partners for an undisclosed sum. Bridgepoint is an international asset management firm with over €20 billion of assets under management.  Commenting on the transaction, PharmaZell CEO Dr. Oliver Bolzern, said: “We […]

    Farmabios Breaks Ground to Expand its Manufacturing Footprint in Gropello Cairoli (Italy)

    As part of an ongoing investment program to enhance PharmaZell Group’s production output, we have initiated the construction of a brand new large steroid building and a new warehouse on the Farmabios premises in Gropello Cairoli (Italy). Construction work began in Dec 2019, a symbolic ground breaking ceremony is planned for Mar 2020. The investment […]

    Renewed GMP Certificate for our Manufacturing Facility Farmabios in Gropello Cairoli (Italy)

    We are very glad to announce that the competent Italian authority (AIFA) has issued a renewed GMP certificate for our Farmabios SpA production facility [http://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do].